Gaetani R, Barile L, Forte E, Chimenti I, Ionta V, Di Consiglio A, Miraldi F, Frati G, Messina E, Giacomello A
Department of Experimental Medicine, Cenci-Bolognetti Foundation, Pasteur Institute, University La Sapienza, Rome, Italy.
Cardiovasc Hematol Agents Med Chem. 2009 Apr;7(2):91-107. doi: 10.2174/187152509787847128.
The aim of cardiac cell therapy is to restore at least in part the functionality of the diseased or injured myocardium by the use of stem/progenitor cells. Recent clinical trials have shown the safety of cardiac cell therapy and encouraging efficacy results. A surprisingly wide range of non-myogenic cell types improves ventricular function, suggesting that benefits may result in part from mechanisms that are distinct from true myocardial regeneration. While clinical trials explore cells derived from skeletal muscle and bone marrow, basic researchers are investigating sources of new cardiomyogenic cells, such as resident myocardial progenitors and embryonic stem cells. In this commentary we briefly review the evolution of cell-based cardiac repair, some progress that has been made toward this goal, and future perspectives in the regeneration of cardiac tissue.
心脏细胞治疗的目的是通过使用干细胞/祖细胞至少部分恢复患病或受损心肌的功能。最近的临床试验已证明心脏细胞治疗的安全性,并取得了令人鼓舞的疗效结果。令人惊讶的是,多种非肌源性细胞类型均可改善心室功能,这表明其益处可能部分源于与真正心肌再生不同的机制。在临床试验探索源自骨骼肌和骨髓的细胞的同时,基础研究人员正在研究新的心肌生成细胞来源,例如驻留心肌祖细胞和胚胎干细胞。在这篇评论中,我们简要回顾基于细胞的心脏修复的发展历程、在这一目标上取得的一些进展以及心脏组织再生的未来前景。